These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19649851)

  • 1. Recent advances in the medicinal chemistry of antisense oligonucleotides.
    Uhlmann E
    Curr Opin Drug Discov Devel; 2000 Mar; 3(2):203-13. PubMed ID: 19649851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oligonucleotide analogues: an overview.
    Matteucci M
    Ciba Found Symp; 1997; 209():5-14; discussion 14-8. PubMed ID: 9383565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicinal chemistry of antisense oligonucleotides--future opportunities.
    Cook PD
    Anticancer Drug Des; 1991 Dec; 6(6):585-607. PubMed ID: 1772571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions between single-stranded DNA binding protein and oligonucleotide analogs with different backbone chemistries.
    Cheng X; DeLong RK; Wickstrom E; Kligshteyn M; Demirdji SH; Caruthers MH; Juliano RL
    J Mol Recognit; 1997; 10(2):101-7. PubMed ID: 9376128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sugar boost: when ribose modifications improve oligonucleotide performance.
    Faria M; Ulrich H
    Curr Opin Mol Ther; 2008 Apr; 10(2):168-75. PubMed ID: 18386229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of antisense oligodeoxynucleotides for transplantation.
    Stepkowski SM
    Curr Opin Mol Ther; 2000 Jun; 2(3):304-17. PubMed ID: 11249625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats.
    Geary RS; Khatsenko O; Bunker K; Crooke R; Moore M; Burckin T; Truong L; Sasmor H; Levin AA
    J Pharmacol Exp Ther; 2001 Mar; 296(3):898-904. PubMed ID: 11181922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.
    Geary RS; Watanabe TA; Truong L; Freier S; Lesnik EA; Sioufi NB; Sasmor H; Manoharan M; Levin AA
    J Pharmacol Exp Ther; 2001 Mar; 296(3):890-7. PubMed ID: 11181921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotides - the way forward.
    Wahlestedt C; Good L
    Curr Opin Drug Discov Devel; 1999 Mar; 2(2):142-6. PubMed ID: 19649940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense treatments for biothreat agents.
    Warfield KL; Panchal RG; Aman MJ; Bavari S
    Curr Opin Mol Ther; 2006 Apr; 8(2):93-103. PubMed ID: 16610760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?
    Henry SP; Geary RS; Yu R; Levin AA
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1444-9. PubMed ID: 11890363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro toxicology and pharmacokinetics of antisense oligonucleotides.
    Crooke RM
    Anticancer Drug Des; 1991 Dec; 6(6):609-46. PubMed ID: 1772572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids.
    Lima WF; Crooke ST
    Biochemistry; 1997 Jan; 36(2):390-8. PubMed ID: 9003192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Building oligonucleotide therapeutics using non-natural chemistries.
    Wilson C; Keefe AD
    Curr Opin Chem Biol; 2006 Dec; 10(6):607-14. PubMed ID: 17049298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotide pharmacokinetics and metabolism.
    Geary RS
    Expert Opin Drug Metab Toxicol; 2009 Apr; 5(4):381-91. PubMed ID: 19379126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
    Oberbauer R
    Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues.
    Gait MJ
    Cell Mol Life Sci; 2003 May; 60(5):844-53. PubMed ID: 12827274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fine tuning of electrostatics around the internucleotidic phosphate through incorporation of modified 2',4'-carbocyclic-LNAs and -ENAs leads to significant modulation of antisense properties.
    Zhou C; Liu Y; Andaloussi M; Badgujar N; Plashkevych O; Chattopadhyaya J
    J Org Chem; 2009 Jan; 74(1):118-34. PubMed ID: 19055352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.